同仁堂（600085）科技(01666)公布，自2025年12月30日起，杜欣女士获委任为公司第九届董事会的非 执行董事。陈飞先生辞任非执行董事亦于同日起生效。 ...

北京同仁堂股份有限公司 关于控股子公司与关联方续订物业租赁框架协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：600085 证券简称：同仁堂 公告编号：2025-044 一、 关联交易概述 (一) 为满足生产经营需求，同仁堂科技及其附属公司拟与同仁堂集团签 订《物业租赁框架协议》，约定同仁堂科技及其附属公司向同仁堂集团（含同仁 堂集团控制的除本公司及本公司控股子公司以外的其他法人或其他组织）承租房 屋及建筑物等物业。鉴于前次协议即将到期，为保证相关业务的正常开展，同仁 堂科技及其附属公司拟与同仁堂集团续订《物业租赁框架协议》，协议期限三年， 1 ● 北京同仁堂股份有限公司（以下简称公司或本公司）之控股子公司北京同仁 堂科技发展股份有限公司（以下简称同仁堂科技）及其附属公司拟与中国北 京同仁堂（集团）有限责任公司（以下简称同仁堂集团）续订《物业租赁框 架协议》，租赁期限三年，用于满足生产经营需求，协议期（2026 年-2028 年） 内每年新增使用权资产上限分别为人民币 11,000 万元、 ...

关于预计日常关联交易的公告 证券代码：600085 证券简称：同仁堂 公告编号：2025-043 北京同仁堂股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 | | | 释 义 | | --- | --- | --- | | 公司、本公司 | 指 | 北京同仁堂股份有限公司 | | 集团公司 | 指 | 中国北京同仁堂（集团）有限责任公司 | | 本集团 | 指 | 北京同仁堂股份有限公司及附属公司 | | 同仁堂集团 | 指 | 中国北京同仁堂（集团）有限责任公司（含其附属公 司，不含本集团） | | 同仁堂健康 | 指 | 北京同仁堂健康药业股份有限公司 | | 同仁堂康养 | 指 | 北京同仁堂康养产业发展有限公司 | | 元 | 指 | 元人民币 | 重要内容提示： 公司拟与集团公司分别签订《采购框架性协议》和《销售框架性协议》， 协议期限为三年。公司预计协议期（2026 年-2028 年）内与同仁堂集团采购日常 关联交易发生额为每年均不超过 150,000 万元（不含税），销售日常关联交易发生 额为每年均 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-045 北京同仁堂股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次：2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相 结合的方式 至2026 年 1 月 16 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 1 (四) 现场会议召开的日期、时间和地点 召开的日期时间：20 ...

北京同仁堂股份有限公司 2026 年第一次临时股东会 会议资料 二零二六年一月 1 | 目 录 | | | --- | --- | | 一、2026 年第一次临时股东会注意事项 | 3 | | 二、2026 年第一次临时股东会会议议程 | 4 | | 三、2026 年第一次临时股东会会议文件 | 6 | | 议案一《关于与关联方签订采购框架性协议及预计年发生额度的议案》 | 6 | | 议案二《关于与关联方签订销售框架性协议及预计年发生额度的议案》 | 7 | | 议案三《关于制定<北京同仁堂股份有限公司董事、高级管理人员薪酬管理办法> | | | 的议案》 | 8 | 2 北京同仁堂股份有限公司 2026 年第一次临时股东会会议资料 北京同仁堂股份有限公司 五、 股东会召开期间，请参会人员将手机等通讯工具关闭或置于静音状态， 自觉遵守会场秩序。为保证每位参会股东的权益，谢绝任何人在会议现场录音、拍 照和录像。 2026 年第一次临时股东会注意事项 尊敬的各位股东及股东代表： 根据《中华人民共和国公司法》《中华人民共和国证券法》、中国证券监督管理 委员会《上市公司股东会规则》和《北京同仁堂股份有限公司章程》等 ...

证券代码：600085 证券简称：同仁堂 公告编号：2025-042 北京同仁堂股份有限公司 第十届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司或本公司）第十届董事会第十八次 会议于 2025 年 12 月 30 日在公司会议室以现场结合通讯会议方式召开。本次会 议通知已提前送达全体董事，与会各位董事均已知悉与本次会议所议事项的相关 必要信息。本次董事会会议应出席董事 11 人，实际出席 11 人。公司部分高级管 理人员列席了本次会议。会议由董事长张朝华女士主持，会议的召开和表决程序 符合《中华人民共和国公司法》及《北京同仁堂股份有限公司章程》（以下简称 《公司章程》）的有关规定。 二、会议审议情况 (一) 审议通过了《关于与关联方签订采购框架性协议及预计年发生额度 的预案》 公司拟与控股股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂 集团）签订《采购框架性协议》，协议期限三年，公司及下属子公司向同仁堂集 团（含其附属公司，不含本公司 ...

格隆汇12月30日丨同仁堂(600085.SH)公布，公司之控股子公司北京同仁堂科技发展股份有限公司（简 称同仁堂科技）及其附属公司拟与中国北京同仁堂（集团）有限责任公司（简称同仁堂集团）续订《物 业租赁框架协议》，租赁期限三年，用于满足生产经营需求，协议期（2026年-2028年）内每年新增使 用权资产上限分别为人民币11,000万元、人民币2,500万元及人民币1,500万元。 ...

Core Viewpoint - The newly implemented "Food Commissioned Production Supervision Management Measures" aims to strengthen the responsibilities of both parties involved in commissioned food production, thereby preventing food safety risks. This regulation will take effect on December 1, 2026, and is a response to recent food safety incidents, particularly the "Antarctic Krill Oil" case [1][3]. Group 1: Regulation Details - The regulation clarifies the scope of commissioned production, defining it as the act of the entrusted party producing food in whole or in part according to the requirements of the commissioning party [3]. - It includes various forms of commissioned production such as trademark licensing, franchising, and OEM production under regulatory oversight [3]. - Both parties must meet specific qualification requirements, including the commissioning party holding a food production and operation license and the entrusted party having the appropriate production capacity and food safety assurance capabilities [3][4]. Group 2: Responsibilities and Reporting - The regulation specifies the responsibilities and obligations of both parties regarding qualification verification, raw material inspection, labeling, food safety self-checks, sample retention, and product recalls [4]. - It mandates that both parties establish a food safety management system and appoint personnel responsible for food safety oversight [4]. - A reporting system is established, requiring both parties to report their commissioned production contracts to local market supervision departments within 10 working days [4]. Group 3: Industry Impact - The "Antarctic Krill Oil" incident has prompted companies like Tongrentang to apologize and initiate self-inspection and rectification measures, highlighting the need for stricter oversight in the industry [5]. - Industry analysts believe that the new regulation will clarify the responsibilities of both parties in OEM collaborations, addressing regulatory gaps and raising operational standards in the food industry [5]. - The introduction of this regulation is seen as a step towards promoting high-quality development in the food sector, especially in light of recent issues faced by leading companies [5].

Core Viewpoint - The newly implemented "Food Commissioned Production Supervision Management Measures" aims to strengthen the responsibilities of both parties involved in food production, particularly in the context of "private label" manufacturing, ensuring better food safety and quality control [1][2][3]. Group 1: Regulatory Framework - The new measures require both the commissioning party and the commissioned party to meet specific qualifications, including obtaining necessary food production licenses and ensuring compliance with food safety standards [1][2]. - The commissioning party must establish a food safety management system and appoint personnel to supervise the commissioned party, holding ultimate responsibility for food safety [1][2]. - Written contracts must be signed before commissioned production, detailing food safety matters, and any changes must be reported to local market supervision departments within ten working days [2][3]. Group 2: Enforcement and Oversight - The measures mandate substantial supervision by the commissioning party over the production activities of the commissioned party, including on-site inspections and the use of information technology for monitoring [2]. - Local market supervision departments are tasked with investigating any illegal activities related to commissioned production and must report findings to the relevant authorities [2]. - The implementation of these measures is expected to enhance local regulatory oversight and ensure timely responses to food safety risks [2][3]. Group 3: Industry Impact - The introduction of these regulations is seen as a necessary step to address the prevalent issues in the "private label" production sector, which has been a significant area of consumer rights violations [3]. - The measures are anticipated to raise the operational thresholds for "private label" collaborations, promoting higher quality standards within the food industry [3]. - The regulations will take effect on December 1, 2026, providing a timeline for companies to adapt to the new requirements [4].

Core Viewpoint - The traditional Chinese medicine sector experienced a decline of 0.9% on December 29, with *ST Changyao leading the drop. The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1]. Group 1: Stock Performance - The following stocks in the traditional Chinese medicine sector showed notable performance: - WoHua Pharmaceutical (002107) closed at 6.33, up 2.43% with a trading volume of 106,100 shares and a transaction value of 65.58 million yuan [1]. - Tianmu Pharmaceutical (600671) closed at 17.39, up 1.81% with a trading volume of 22,600 shares and a transaction value of 39.17 million yuan [1]. - Weikang Pharmaceutical (300878) closed at 25.75, up 0.66% with a trading volume of 20,500 shares and a transaction value of 53.04 million yuan [1]. - Tongrentang (600085) closed at 32.46, up 0.65% with a trading volume of 168,300 shares and a transaction value of 221 million yuan [1]. - Yunnan Baiyao (000538) closed at 56.69, down 0.02% with a trading volume of 61,100 shares and a transaction value of 346 million yuan [1]. Group 2: Capital Flow - The traditional Chinese medicine sector saw a net outflow of 689 million yuan from institutional investors, while retail investors contributed a net inflow of 462 million yuan [2]. - Notable capital flows for specific stocks include: - Tongrentang (600085) had a net inflow of 28.03 million yuan from institutional investors, but a net outflow of 19.15 million yuan from retail investors [3]. - Wanbangde (002082) experienced a net inflow of 12.49 million yuan from institutional investors, with a net outflow of 9.44 million yuan from retail investors [3]. - Ma Yinglong (600993) had a net inflow of 5.11 million yuan from institutional investors, while retail investors saw a net inflow of 3.19 million yuan [3].